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Clinical trials are designed to evaluate interventions that prevent, diagnose or treat a
health condition and provide the evidence base for improving practice in health care.
Many health professionals, including those working within or allied to hearing health,
are expected to conduct or contribute to clinical trials. Recent systematic reviews of
clinical trials reveal a dearth of high quality evidence in almost all areas of hearing health
practice. By providing an overview of important steps and considerations concerning the
design, analysis and conduct of trials, this article aims to give guidance to hearing health
professionals about the key elements that define the quality of a trial. The article starts
out by situating clinical trials within the greater scope of clinical evidence, then discusses
the elements of a PICO-style research question. Subsequently, various methodological
considerations are discussed including design, randomization, blinding, and outcome
measures. Because the literature on outcome measures within hearing health is as
confusing as it is voluminous, particular focus is given to discussing how hearing-
related outcome measures affect clinical trials. This focus encompasses how the choice
of measurement instrument(s) affects interpretation, how the accuracy of a measure
can be estimated, how this affects the interpretation of results, and if differences are
statistically, perceptually and/or clinically meaningful to the target population, people
with hearing loss.
Keywords: clinical trials, outcome measures, minimal important difference, interventions, hearing loss, hearing-
related outcomes, clinically meaningful
INTRODUCTION
Clinical trials are a type of research that study health interventions and evaluate their effects on
human health outcomes (World Health Organisation, 2018). James Lind is credited for conducting
the first clinical trial in humans (see for example, Collier, 2009). In 1747, Lind investigated different
treatments for scurvy. He demonstrated that, in sailors living under the same conditions, it was
only those who were provided with fruit (specifically, Vitamin C) that recovered. The purpose of
the intervention in a clinical trial might be to prevent, diagnose or, in the case of Lind, treat a health
condition. The conduct and quality of clinical trials is critical since they provide the evidence base
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for improving practice in health care. Many health professionals,
including those working within or allied to hearing health, are
expected to conduct or contribute to clinical trials.
Grading of Recommendations, Assessment, Development,
and Evaluations (GRADE; Atkins et al., 2004) is a framework
commonly used to assess quality of evidence based on
study limitations, inconsistency, indirectness, imprecision, and
publication bias, e.g., outcomes from non-randomized studies
without blinding would be considered low. As with many areas of
healthcare, systematic reviews in hearing science and audiology
have highlighted a dearth of good quality clinical trials. Notable
in this context are reviews published by the National Institute
for Health and Care Excellence (NICE), a public body sponsored
by the United Kingdom government that provides evidence to
improve health and social care, and the Cochrane Database of
Systematic Reviews (CDSR), the leading journal and database for
systematic reviews in health care:
1. NICE published reviews as part of national guidelines
(NG) on assessment and management of adult hearing
loss (NG98; National Institute for Health and Care
Excellence, 2018), and assessment and management of
tinnitus (NG155; National Institute for Health and Care
Excellence, 2020). Both guidelines include around 20
systematic reviews on areas of uncertainty or variation in
clinical practice. 50–60% of the systematic reviews revealed
no evidence on which to base clinical recommendations.
The remaining 40–50% of the systematic reviews identified
supporting evidence; however, the quality of the individual
studies was mostly graded as low due to risk of
bias (see later).
2. CDSR published a review of the effects of hearing aids in
everyday life for people with mild to moderate hearing loss.
This revealed benefits; however, the evidence was based
on five studies, and their quality was graded as moderate
(Ferguson et al., 2017).
The current article redresses the limited evidence base by
providing an overview of the design, analysis and conduct of
clinical trials. Judicious use of selected studies highlight potential
methodological limitations as well as examples of good practice.
The aim is to provide guidance to hearing health professionals
about the key elements that define the quality of a trial. Detailed
information is provided on outcome measures, and on how
hearing-related outcome measures affect clinical trials: (i) how
the choice of measurement instrument(s) affects interpretation,
(ii) how the accuracy of a measure can be estimated, (iii) how
this affects the interpretation of results, and (iv) if differences
are statistically, perceptually and/or clinically meaningful to the
target population, people with hearing loss.
IDENTIFYING THE RESEARCH
QUESTION
Before designing a clinical trial, an essential starting point
is to craft a carefully worded research question. Evidence-
based medicine provides an explicit framework for formulating
research questions that can be used when: (i) designing clinical
trials or (ii) searching the literature for studies to be included in
a systematic review of the literature. The four components of the
question are contained in the PICO mnemonic: Population (P),
Intervention (I), Comparator (C), and Outcome (O).
An example of a research question in the PICO format
would be, “What is the clinical- and cost-effectiveness [outcome]
of monitoring and follow-up regimes [intervention] for adults
offered NHS hearing aids for the first time [population],
compared to usual care [comparator]. The same approach
was used by NICE when preparing the clinical guidelines
mentioned earlier.
THE HIERARCHY OF EVIDENCE
Hierarchies of evidence, developed to aid the interpretation
and evaluation of research findings, are a core principal of
Evidence-Based Practice (EBP). They rank research according to
its validity, and in particular, risk of bias. While many research
study designs exist (e.g., cohort, case-controlled, cross-sectional
and case series/reports), well conducted randomized controlled
trials (RCT) are generally considered the gold standard because
they provide the lowest risk of bias and, hence, the highest quality
of evidence. The first step to building high-quality evidence
for clinical practice should always be a recent well-conducted
systematic review following a standardized reporting method
such as the Preferred Reporting Items for Systematic Reviews
(PRISMA).1 An alternative design to a RCT is an observational
study, so called because the researcher observes individuals
without manipulation or intervention. These can be useful in
instances where RCTs are not appropriate. For example, the
effectiveness of parachutes has not been proven in a RCT where
participants are randomized to parachute or placebo (Smith and
Pell, 2003). In this example, the effect size would be very large
because death and serious trauma is much more likely in the
placebo group. However, when effect sizes are smaller (which
applies to the vast majority of questions), confounds and bias
may distort the effect size. In such cases, all efforts should be
made to set up an RCT. To appreciate the potential disadvantages
of observational designs compared to a RCT trial, consider the
following study by Noble and Gatehouse (2006). They used an
observational design to compare existing adult hearing aid users
of bilateral or unilateral hearing aids. Their results showed that
bilateral hearing aids offer advantages in demanding and dynamic
listening situations that were not conferred by unilateral hearing
aids. However, due to the design it is not possible to know if
the natural selection of groups introduced a bias and led to a
miss-estimation of the effect.
Systematic errors have the potential to result in the wrong
conclusions about the effects of the intervention. The risk of
systematic errors differs between designs and is more likely
for observational designs than RCT. Two types of systematic
errors are biases and confounds. An example of an experimental
confound is age. If, for example, a higher proportion of older
1http://www.prisma-statement.org
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people receive the intervention than the control, age-related
differences, unrelated to the intervention, could affect the results.
An example of bias is when researchers or participants expect
the new intervention to generate a better outcome. For example,
Dawes et al. (2011, 2013) examined the effect of participant
expectation when comparing two hearing aids that were identical
except one was labeled “new” and the other “conventional.” Mean
performance with the hearing aid labeled “new” was significantly
higher on all outcome measures. These studies demonstrate
that placebo effects can, and do, affect hearing aid trials. Initial
preferences can dominate outcomes, as shown in hearing-aid
RCTs investigating unilateral and bilateral fittings. For example,
Cox et al. (2011) showed that 80% of participants could be
predicted based on initial preference for one or two hearing
aids. Additionally, Naylor et al. (2015) demonstrated that the
outcome for the same technology was influenced by how involved
the participant was in the fitting process. Therefore, measuring
preferences and attitudes related to the intervention should be
included to help control for such confounds in the analysis.
Another set of biases are performance and detection biases
when systematic differences exist between groups in terms of
care and measurement of outcomes, which can be minimized
through blinding. By reducing the risk of confounds and bias, any
difference in outcome at the end of the trial can be more robustly
attributed to the intervention.
Clinical trials in humans are commonly classified into four
types or “phases,” depending on their aim. Within a trial, there
are typically four stages to its preparation and operation: pre-
trial, trial set-up, during trial and end of trial. Table 1 details the
phases and gives examples of activities carried out at each stage
of any clinical trial. Hackshaw (2009) provides a comprehensive
overview of the design, conduct and analysis of trials, ideal for
busy health professionals who read or undertake clinical research.
METHODOLOGICAL CONSIDERATIONS
In order to ensure that clinical trials are executed well, some
key methodological issues need to be considered. These include
design, randomization, and blinding; all three pose particular
challenges to running a hearing-specific RCT.
Design
A cardinal decision in every clinical trial is the choice of design.
Fundamentally, the research team has the decision between
two designs: a crossover design where participants receive all
interventions in a randomized (or counter-balanced) order, or
a parallel-group design where participants are randomized to a
single intervention (Figure 1). An advantage of the crossover
design is that it is a within-groups design: each participant acts
as their own control, increasing statistical power. In hearing
studies, where the emphasis is usually less on cure and more on
benefit and quality of life (QoL), our preference is judicious use
of crossover trials. Marriage et al. (2004) used a crossover design
when comparing three prescriptions for hearing aid gain settings;
there was, however, an issue in its crossover design: tolerance for
greater gain increased over the course of the trial regardless of
TABLE 1 | Phases (types) of clinical trials and examples of key activities in each
clinical trial process.
Phase Explanation
One An exploratory investigation of safety and the effects of dosage
in a small number of healthy participants.
Two A preliminary estimate of efficacy (i.e., the potential of the
intervention to provide benefit), in a small number of
participants with the specific health condition.
Three A definitive trial of effectiveness, involving a relatively large
number of participants who are randomized to the
intervention(s) or control.
Four Monitors side effects and how well the intervention works over
a longer period and in a very large number of participants.
Stage Key activities
Pre-trial • Formulate the PICO research question
• Design trial
Trial set-up • Protocol and ethics




The trial • Collect and store data
• Regularly review for protocol adherence
End of trial • Lock database and undertake statistical analysis
• Identify and deal with missing data
• Disseminate trial findings
intervention order. Hearing-aid studies using a crossover design
often do not include washout periods (Arlinger et al., 2008;
cf. Cox et al., 2016) which may reduce carryover effects from
one intervention to the next. For hearing training and support
interventions, crossover randomization would confound the
effect of the intervention with its order (i.e., outcomes following
a training period would not be expected to be equivalent to
outcomes preceding a training period), hence parallel designs
have been used (e.g., Meijerink et al., 2020). A parallel group
design contains more natural variation, making it harder to know
whether any variation in results is due to the intervention or
differences between the participants in the groups. Humes et al.,
2017 used a parallel design to study the efficacy of generically fit
hearing aids vs. individually fit and placebo devices, randomly
assigning participants to one of the three arms. The population
to be tested also needs to be considered; in interventions with
hearing-aid users, for example, halo effects may lead to greater
effects for new compared to experienced users (Ivory et al., 2009).
Randomization
In an RCT, a sample of participants from the population of
interest are randomly allocated to receive the experimental
or control/comparator intervention (the latter may be “usual
care” or a placebo). The purpose of randomization is to
reduce systematic differences in the characteristics of participants
allocated to each group. In the case of Lind’s scurvy trial,
the population of interest (sailors with scurvy) were randomly
allocated to receive interventions including seawater, nutmeg
and garlic and fruit. In hearing science, within-group crossover
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FIGURE 1 | Schematic example of a (A) parallel and (B) crossover design for a two-arm clinical trial. In both designs, a sample is taken from the target population,
randomly allocated to intervention or control group. In the crossover design, the same participants are then given the other intervention after an interim washout
period (At).
designs are much more common. The type of randomization
can be critical to allocation and analyses of the trial (Lachin
et al., 1988). For hearing-related RCTs the sample size is
usually <200, so simple randomization could lead to imbalanced
group sizes. When using multiple clinics or outcomes with
known covariates, both common in hearing trials, stratified
randomization is necessary to insure reasonably balanced
allocation across sites and/or covariates. For example, Humes
et al. (2017) first stratified participants by unaided speech-in-
noise performance, an expected covariate with their outcomes,
before then allocating each stratum randomly to a different
arm. A newer randomization technique, called merged block
(van der Pas, 2019), combines block and simple randomization
while avoiding the biases of both, and could be well-suited
to hearing RCTs.
Blinding
Blinding is a critical methodological feature of RCTs that reduces
the risks of confounds and biases. Ideally, blinding should
extend to everyone associated with the trial including clinicians,
data collectors and data analysts. Clinical trials are described
as double-blinded if both the researcher and participant are
unaware of treatment allocation. A single-blinded study usually
means the participant is unaware which treatment has been
allocated. Blinding is more difficult to incorporate in trials
of medical devices and surgical interventions than trials of
medical therapies, which usually include placebo medications.
Cox et al. (2016) investigated the effect of basic vs. premium
hearing-aid features on subjective outcomes in a single-blinded
study with no statistically significant difference between feature
levels. In theory, this could have been a double-blinded study
if the researcher responsible for data collection and analysis
was also blinded from the hearing aid prescription and fitting.
For many studies involving standard hearing aids, the devices
need to be individually fit, potentially unblinding the audiologist.
The audiologist would then need to be outwith the research
team and blind to the aims of the study. In the Cochrane
systematic review evaluating the effects of hearing aids for mild-
to-moderate hearing loss in adults (Ferguson et al., 2017), the
risk of performance and detection bias was rated as high because
blinding was inadequate or absent. More recently, there have
been attempts to maintain blinding. The use of placebo hearing
aids allows blinding if they are visibly identical to active hearing
aids. Studies by Adrait et al. (2017) and Humes et al. (2017) both
used placebo hearing aids that provided minimal gain. These
studies demonstrate that it is possible to blind participants and
outcome assessors in hearing aid trials where the amplification
characteristics can be concealed. Also, in a double-blinded RCT
investigating the effectiveness of sound therapy in people with a
reduced audiometric dynamic range, Formby et al. (2015) used
conventional and placebo-controlled sound generators where the
output of the placebo decayed to silence after 1 h of use in the ear.
HEALTH-RELATED OUTCOME
MEASURES
The most important question of any clinical trial is whether the
trial’s intervention was successful. The question is answered by
means of primary and secondary outcome measures. Primary
outcome measures capture the most evident or most important
changes connected to the intervention (Vetter and Mascha,
2017). Secondary outcome measures assess aspects of the
intervention in finer detail, for example, in order to understand
mechanisms of change.
Once it is clear what the main expected change is, the vital
question is how to capture this change. Outcome measurements
can be objective (physiological or behavioral) or subjective,
generalized or specific and clinician- or patient-reported. Other
important considerations are the period being measured, and the
measures’ generalizability, reliability, and relevance.
Objective Versus Subjective Outcomes
Some changes are only measurable by one type of outcome.
One example is satisfaction, which can only be assessed as a
subjective measure. However, subjective measures always need
to be treated with caution. Satisfaction is a good example as the
aforementioned study by Humes et al. (2017) found relatively
good satisfaction with a placebo hearing aid.
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For other outcomes, both objective and subjective measures
exist. The combination of different instruments, such as objective
and subjective measures of change in hearing ability, often
will provide greater sensitivity and interpretability than a single
measure. Further, using multiple measures will help counteract
any dependence a single outcome has on participants or
practitioners when blinding is an issue (e.g., the intervention
difference cannot be concealed). However, the more outcome
measures included in a trial, the greater the risk that results do
not concur and potentially lead to opposing interpretations. One
example is hearing aid use, which can differ between patients’
self-reported use and their devices’ data logging. For example,
Solheim and Hickson (2017) reported a mean of 8.4 and 6.1 h for
self-report and data logging, respectively. A possible alternative
to measuring hearing aid use by data logging is to measure
persistence through requests for supply of batteries (Zobay et al.,
2021). Future measures may also be able to tap into usefulness –
the desired outcome for which use and persistence are surrogates.
Outcome Measurement Period
Deciding on the time point of assessment is particularly difficult,
as it needs to include considerations of the temporal nature of
the intervention. For hearing-aid trials, there may be an auditory
acclimatization period before achieving full objective benefit
(Dawes and Munro, 2017), whereas initial subjective benefit may
decline over time (Humes et al., 2002). In addition, care must
be taken to monitor the environments during the measurement
period (e.g., via data logging) to ensure it is homogenous (Humes
et al., 2018). For other studies, including training studies, the
main interest might be in the time course and longevity of change.
In the case of the latter, it needs to be carefully considered whether
change is best assessed immediately after the intervention, or 6
weeks, 6 months or a year later. Wisely chosen test intervals may,
for example, show whether training effects persist or weaken after
the end of regular training (Henshaw et al., 2021).
Generalizability of Outcomes
The question of generalizability reflects the tension between
choosing standardized tools that are validated but have limited
specificity to a particular health condition versus tools that
are specific to a health condition but possibly newly created
or modified, and often insufficiently validated. One example
are QoL measures. As shown by Heinrich et al. (2015), a
standardized generic QoL questionnaire such as the EQ-5D may
not show any correlation with speech-in-noise performance,
while a hearing-specific extension, the HR EQ-5D, does, but
has not been appropriately standardized and validated. In the
interest of building a body of evidence that can support CDSR
and healthcare-system decisions (e.g., NICE) to improve clinical
practice, some standardization and validation of outcomes
measures will be essential. The Health Utility Index (HUI3) may
provide a compromise as it is a standardized tool that has shown
some sensitivity to hearing-aid provision (Barton et al., 2004).
A number of initiatives have been set up to understand
what measurement instruments are being used within a field,
how accurate, reliable and valid they are for what they aim
to assess and how a core minimum outcome set could look
like. Initiatives such as COMET (Core Outcome Measures in
Effectiveness Trials)2 bring together research groups interested
in the development and application of agreed standardized sets
of outcomes that should be measured and reported as minimum
core sets in all clinical trials of a specific condition. One hearing-
aid related outcome measure that was developed in a consortium
resembling (but prior to) COMET is the seven-item International
Outcome Inventory for Hearing Aids (IOI-HA; Cox et al., 2000).
Outcome Reliability
If the validity and reliability of an outcome measure are
in doubt, any interpretation of the results may suffer.
COSMIN (Consensus-based Standards for the selection of
health Measurement INstruments)3 is an expert-led initiative
that developed standards for the evaluation of health-status
measures. Any outcome measure included in a trial should
conform to their standards. A critical aspect of an outcome
measure’s methodological quality is its retest reliability. There are
various ways of calculating reliability estimates (see Heinrich and
Knight, 2020 for a discussion). The broader point, however, is
that the retest reliability for many hearing outcome measures is
rather poor, leading to “non-trivial” minimum/critical differences
required to show an effect of an intervention (Weinstein et al.,
1986; Cox and Rivera, 1992). Retest reliability and critical
differences are also rather poor for standard speech-in-noise tests
(Heinrich and Knight, 2020), making it a challenge to use them
as outcome measures for a hearing RCT in which small effects
may be expected.
Relevance of Outcomes
Statistical significance is only one aspect of change. Equally
important is that changes are perceptually noticeable and
clinically relevant. Often it is possible to show that a change
is statistically significant, particularly on a group level, but not
perceptually noticeable or meaningful for an individual (e.g.,
improvement in signal-to-noise ratio that was not perceived by
the participants; McShefferty et al., 2015, 2016), hence may lack
relevance for the patient. Relevance at the clinic level can be
achieved from comparing results against a (minimal) clinically
important difference [(M)CID], a stakeholder-defined threshold
of the proportional alleviation of a dysfunction or reduction in its
prevalence. As hearing-loss interventions are compensatory, not
restorative, (M)CIDs can seem ill suited to measuring clinically
important differences, though it is possible, as demonstrated by
Skarżyński et al. (2018) for tinnitus improvement after middle
ear surgery. By first defining the threshold for a successful
intervention, abetted by using validated measures that have a
no-change midpoint, it is possible to report the percentage in
alleviation for a particular hearing problem.
REPRODUCIBILITY
The reproducibility of research is key to scientific advancement. It
means that comparable results are obtained by methodologically
2https://www.comet-initiative.org/
3https://www.cosmin.nl/
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closely matched but independent studies. Many fields, including
biomedical science, suffer from a reproducibility crisis (de Vries
et al., 2018) led by poor research practices and a well-established
bias in scientific journals to preferentially publish novel and
statistically significant findings which support the experimental
hypothesis (Fanelli, 2012; Open Science Collaboration, 2015).
Reproducibility can be increased in a number of ways, many of
them applicable to clinical trials research. First, it is important
to ensure that every phase of the research cycle is as transparent
and open as possible, so that readers can fully evaluate the
work. This research practice is referred to as “open science”
(Kathawalla et al., 2021) and often contains the following three
components: pre-registration, open data and open materials
(Svirsky, 2019). Pre-registration makes information available in
the public domain about the design and conduct of an intended
study before collection of data (Munro and Prendergast, 2019).
Open data and materials refers to depositing the datasets and
test materials from the trial in the public domain. In addition to
adhering to open science principles, the robustness of results are
further bolstered by conducting collaborative multi-laboratory
studies to understand the conditions for and boundaries of
replication (Heinrich and Knight, 2020).
CONCLUSION
There is a dearth of high quality evidence to support much of
our existing clinical practice. This can be addressed by clinical
trials but only if the conduct is rigorous and the quality is
high. Good quality clinical trials have a research question based
on PICO guidelines, follow best practice on methodological
issues such as design, randomizing treatments and full blinding
(participants and assessors) and choose optimal outcomes to
assess the research questions in the correct timeframe and with
reliability and validity. The importance of transparency and open
science practices cannot be over-estimated.
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